This disclosure relates to procedures for administering a blockade of the sphenopalatine ganglion (“SPG”). Methods may include advancing a catheter through nostril at least 8 cm. Methods may include advancing the catheter through an inferior meatus. Methods may include causing the catheter to bend after contacting posterior wall of the nasal cavity. Methods may include advancing the catheter superiorly to a position posterior to the middle turbinate. Methods may include advancing the catheter superiorly to a position posterior to the superior turbinate. Methods may include advancing the catheter superiorly into a sphenoethmoid recess. Methods may include bringing a distal tip of the catheter in contact with the SPG. Methods may include ejecting an anesthetic from a distal tip of the catheter and bathing the SPG to administer a blockade of the SPG.

A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis involved impregnating an absorbent tip of an applicator with the formulation, the applicator having a rigid rod having the absorbent tip at a distal end thereof, and inserting the applicator straight into a nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip.

A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis involved impregnating an absorbent tip of an applicator with the formulation, the applicator having a rigid rod having the absorbent tip at a distal end thereof, and inserting the applicator straight into a nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip.

Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.

A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents (TA) within the GI tract and in particular to an antrum wall (AW). Particular embodiments provide a swallowable device (SD) such as a capsule for delivering drugs or other TA into the AW. The SD may contain a pressure sensitive component or assembly which triggers release and insertion of a therapeutic agent preparation (TAP) comprising at least one TA into the AW in response to external pressure, such as pressure applied to the swallowable capsule or other SD by antrum contractions. Particular embodiments of the SD may be shaped so that they self-align within an antrum to properly orient before injection of the TAP into the AW. Embodiments of the invention are particularly useful for orally delivering drugs or other TAs which are degraded within the GI tract and require parenteral injection.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents (TA) within the GI tract and in particular to an antrum wall (AW). Particular embodiments provide a swallowable device (SD) such as a capsule for delivering drugs or other TA into the AW. The SD may contain a pressure sensitive component or assembly which triggers release and insertion of a therapeutic agent preparation (TAP) comprising at least one TA into the AW in response to external pressure, such as pressure applied to the swallowable capsule or other SD by antrum contractions. Particular embodiments of the SD may be shaped so that they self-align within an antrum to properly orient before injection of the TAP into the AW. Embodiments of the invention are particularly useful for orally delivering drugs or other TAs which are degraded within the GI tract and require parenteral injection.

The present invention is pursuant to the fields of Pharmacy and Medicine. More specifically, the invention provides an intraurethral dosage form of liquid or gel medication for men or women. In one embodiment, an applicator provides advantages in its use, facilitating the application of pharmaceutical compositions directly into the urethral channel and providing fast local effect without substantial risk. The invention provides a dosage form and route of administration for several medications, being particularly useful for the application of anti-inflammatory and/or anesthetic medications, for the treatment of female cystitis, for modulating female genital sensitivity and/or for modulating the erectile function in man, being an advantageous dosage form alternative to the oral or injectable administration of medications or even the intraurethral administration of pills.

The present invention is pursuant to the fields of Pharmacy and Medicine. More specifically, the invention provides an intraurethral dosage form of liquid or gel medication for men or women. In one embodiment, an applicator provides advantages in its use, facilitating the application of pharmaceutical compositions directly into the urethral channel and providing fast local effect without substantial risk. The invention provides a dosage form and route of administration for several medications, being particularly useful for the application of anti-inflammatory and/or anesthetic medications, for the treatment of female cystitis, for modulating female genital sensitivity and/or for modulating the erectile function in man, being an advantageous dosage form alternative to the oral or injectable administration of medications or even the intraurethral administration of pills.

A microparticle for drug loading, a drug loading microparticle, a particle containing tube, and an implantation system for the microparticle. The microparticle for drug loading includes a housing (31) and a drug loading part (34) located inside the housing and is used for being implanted into body tissues by means of a puncture needle (5); the housing (31) is provided with at least one micro-hole (33) running through the wall thickness of the housing (31); and the drug loading part (34) is located inside the housing (31) and is used for loading drugs. The microparticle for drug loading/drug loading microparticle can achieve different types of drug loading and different release speeds, can be directly implanted into tissues, and have the technical advantages of both microspheres and radioactive particles.